Product Details:

CasNo： 68377-91-3

Molecular Formula： C15H22ClN3O2S3

Appearance： White to orange, or turning green powder

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

Arotinolol Hydrochloride 

CAS：68377‑91‑3

Brand name：Almarl®（阿尔马尔）

Developer：Sumitomo Pharma（住友制药）

Drug class：Dual‑action α₁ /non‑selective β‑adrenergic receptor antagonist（α,β 受体阻滞剂）

Molecular Weight：408.97

Approved: Japan 1985; China later authorized; oral tablet dosage form

✅ Official Indication

Arotinolol hydrochloride tablets are indicated for the treatment of adult patients with:

1. Mild‑to‑moderate essential hypertension
2. Angina pectoris
3. Tachyarrhythmias (tachycardiac arrhythmia)
4. Essential tremor

Dosage note: Oral administration, typical dose range 10‑40 mg daily, divided into twice‑daily dosing; maximum daily dose shall not exceed 30 mg for essential tremor。

📄 Detailed Product English Description

Arotinolol hydrochloride is an orally‑active dual‑action adrenergic receptor antagonist. It competitively blocks both non‑selective β‑adrenergic receptors (β₁, β₂) and α₁‑adrenergic receptors, with an approximate α‑ / β‑blocking potency ratio of 1 : 8. The API is white to off‑white crystalline powder, soluble in water and aqueous alcohol. β‑receptor blockade reduces heart rate, myocardial contractility, cardiac output and suppresses renin release from renal juxtaglomerular cells. Concurrent α₁‑receptor antagonism relaxes vascular smooth muscle, produces peripheral vasodilation and lowers total peripheral resistance. Unlike pure β‑blockers, the additional α‑blocking effect avoids the tendency of peripheral vasoconstriction. For hypertension, the combined receptor inhibition achieves sustained blood‑pressure reduction. In angina pectoris, it decreases myocardial oxygen consumption by suppressing excessive cardiac sympathetic activity and improves myocardial oxygen supply‑demand balance. Anti‑arrhythmic effect originates from reduced sinus‑node automaticity and slowed atrioventricular conduction. Blockade of skeletal‑muscle β₂‑receptors suppresses pathological muscle oscillation and relieves symptoms of essential tremor. Finished pharmaceutical product is oral tablet. Therapy should be initiated at low dose and titrated gradually. Abrupt discontinuation is not recommended; dose tapering is required to prevent rebound hypertension or angina exacerbation.

⚠️ Safety brief note

Major adverse events include bradycardia, hypotension, dizziness, fatigue. Beta‑2‑blockade may trigger bronchoconstriction; contraindicated in patients with bronchial asthma, severe bradycardia, atrioventricular block, cardiogenic shock. Gradual dose tapering is mandatory before discontinuation. Caution in diabetic patients and patients with hepatic or renal impairment.